Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD)

被引:28
|
作者
Morrison, CE
Borod, JC
Brin, MF
Hälbig, TD
Olanow, CW
机构
[1] NYU, Med Ctr, Comprehens Epilepsy Ctr, New York, NY 10016 USA
[2] Mt Sinai Sch Med, Dept Neurol, New York, NY USA
[3] CUNY Queens Coll, Dept Psychol, New York, NY USA
[4] CUNY, Grad Ctr, New York, NY USA
[5] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA
[6] Allergan LLC, Irvine, CA USA
关键词
Parkinson's disease; levodopa; cognitive; depression;
D O I
10.1007/s00702-004-0145-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although improved cognition has been reported in patients with mild Parkinson's disease (PD) following the administration of levodopa, mixed results have been found in moderately-to-severely affected PD patients (MSPD), particularly in studies conducted since 1980. In the present study, 16 MSPD patients were tested on separate days, once following overnight levodopa withdrawal and once while optimally treated. A battery of neuropsychological tests that assess a range of cognitive functions (i.e., attention, language, visuospatial, memory, and executive), as well as a measure of depression, were used. Although patients performed better on a measure of confrontation naming in the untreated than in the treated condition, there were no significant differences for any of the other cognitive variables or for the depression scale variable. Thus, these data suggest that there are generally no adverse or beneficial effects of levodopa therapy on cognition in MSPD patients.
引用
收藏
页码:1333 / 1341
页数:9
相关论文
共 50 条
  • [21] Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
    Howard, Robert
    McShane, Rupert
    Lindesay, James
    Ritchie, Craig
    Baldwin, Ashley
    Barber, Robert
    Burns, Alistair
    Dening, Tom
    Findlay, David
    Holmes, Clive
    Hughes, Alan
    Jacoby, Robin
    Jones, Rob
    Jones, Roy
    McKeith, Ian
    Macharouthu, Ajay
    O'Brien, John
    Passmore, Peter
    Sheehan, Bart
    Juszczak, Edmund
    Katona, Cornelius
    Hills, Robert
    Knapp, Martin
    Ballard, Clive
    Brown, Richard
    Banerjee, Sube
    Onions, Caroline
    Griffin, Mary
    Adams, Jessica
    Gray, Richard
    Johnson, Tony
    Bentham, Peter
    Phillips, Patrick
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10): : 893 - 903
  • [22] Cognitive functioning and hallucinations in Parkinson's disease
    Stebbins, GT
    Bernard, BA
    Fan, WQ
    Leurgans, SE
    Goetz, CG
    ANNALS OF NEUROLOGY, 2005, 58 : S56 - S56
  • [23] Cognitive functioning in idiopathic Parkinson's disease
    Chatterjee, P.
    Joshi, D.
    Kumar, B.
    MOVEMENT DISORDERS, 2013, 28 : S200 - S200
  • [24] Pharmacological treatment in moderate-to-severe Alzheimer's disease
    Hsiung, Ging-Yuek Robin
    Feldman, Howard H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (15) : 2575 - 2582
  • [25] Cardiovascular effects of levodopa in Parkinson's disease
    Noack, Cornelia
    Schroeder, Christoph
    Heusser, Karsten
    Lipp, Axel
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (08) : 815 - 818
  • [26] Cognitive functioning in Parkinson's disease and Parkinson plus syndrome
    Mina, S.
    Verma, V. K.
    Anand, K. S.
    MOVEMENT DISORDERS, 2016, 31 : S78 - S79
  • [27] EFFECTS OF LEVODOPA ON FUNCTIONAL CONNECTIVITY IN PARKINSON'S DISEASE PATIENTS WITH MILD COGNITIVE IMPAIRMENT
    Sreenivasan, K.
    Zhuang, X.
    Ritter, A.
    Caldwell, J.
    Cordes, D.
    Mari, Z.
    Mishra, V.
    PARKINSONISM & RELATED DISORDERS, 2023, 113 : 14 - 14
  • [28] Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease
    Newhouse, P
    Potter, A
    Corwin, J
    DRUG DEVELOPMENT RESEARCH, 1996, 38 (3-4) : 278 - 289
  • [29] Effects of donepezil in patients with moderate-to-severe Alzheimer's disease discontinuing memantine monotherapy
    Sakka, P.
    Tsolaki, M.
    Hort, J.
    Hager, K.
    Soininen, H.
    Lopez-Pousa, S.
    Li, C.
    Schwam, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 58 - 58
  • [30] Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
    Peyrin-Biroulet, Laurent
    Chapman, J. Casey
    Colombel, Jean-Frederic
    Caprioli, Flavio
    D'Haens, Geert
    Ferrante, Marc
    Schreiber, Stefan
    Atreya, Raja
    Danese, Silvio
    Lindsay, James O.
    Bossuyt, Peter
    Siegmund, Britta
    Irving, Peter M.
    Panaccione, Remo
    Cao, Qian
    Neimark, Ezequiel
    Wallace, Kori
    Anschutz, Toni
    Kligys, Kristina
    Duan, W. Rachel
    Pivorunas, Valerie
    Huang, Xiu
    Berg, Sofie
    Shu, Lei
    Dubinsky, Marla
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (03): : 213 - 223